Cytek Biosciences Announces $50 Million Stock Repurchase Program
Cytek Biosciences announced a $50 million stock repurchase program, approved by its Board of Directors. This initiative aims to buy back shares of its common stock, listed under the Nasdaq symbol CTKB, up until December 31, 2024, unless modified. Repurchases will take place on the open market or through private transactions, adhering to SEC Rule 10b-18 and legal requirements. The program's extent and timing will depend on liquidity, cash flow, and market conditions. However, Cytek is not obliged to buy back any specific amount and may alter or suspend the program at any time.
- Board-approved $50 million stock repurchase program.
- Potential for share price support through buybacks.
- Program running until December 31, 2024, providing flexibility.
- Adherence to SEC Rule 10b-18 ensures legal compliance.
- No obligation to repurchase a specific amount.
- Program can be modified or suspended at any time.
- Repurchase decisions depend on liquidity, cash flow, and market conditions, adding uncertainty.
Insights
Cytek Biosciences' announcement of a
It’s essential to note the flexibility in the buyback program — it doesn't obligate the company to repurchase any specific amount of stock, allowing it to react to market conditions and cash flow availability. This flexibility is advantageous, enabling the company to maintain financial stability while potentially providing returns to shareholders through stock price appreciation.
For retail investors, understanding that the repurchase will be conducted in compliance with SEC's Rule 10b-18 is crucial. This rule provides a safe harbor against accusations of market manipulation, implying that the buyback will be managed transparently and ethically. Investors might see this as a strategic move to optimize shareholder value.
However, the timing and market conditions will play a significant role. If the market perceives the buyback as a signal of underlying strength, it could boost investor confidence, leading to a stock price increase in the short term. Conversely, if the broader market conditions are unfavorable, the impact might be muted.
Overall, the buyback program represents a vote of confidence from Cytek Biosciences' management, but investors should monitor the company's financials and market conditions closely in the coming months.
From a market perspective, Cytek Biosciences' stock repurchase program can be seen as a strategic move to bolster shareholder value. This approach may help mitigate any potential stock price volatility by providing a cushion against market fluctuations. Additionally, the buyback could indicate that the company has sufficient liquidity and confidence in its cash flow generation capabilities.
For retail investors, it's important to recognize that stock buybacks can lead to a more favorable earnings per share (EPS) ratio. By reducing the number of outstanding shares, the company's earnings are spread over fewer shares, potentially enhancing per-share earnings and attracting more investor interest.
Another aspect to consider is investor sentiment. Announcing a buyback program often sends a positive signal to the market, suggesting the company believes its stock is undervalued and is taking steps to correct this. This can lead to increased investor confidence and potentially higher stock prices.
Yet, investors should remain cautious and consider the broader market context. If market conditions are turbulent or if the company faces unforeseen financial challenges, the expected positive effects of the buyback could be diminished. Hence, while buybacks are generally seen as positive, they should be evaluated within the broader market and economic environment.
FREMONT, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the repurchase of up to an aggregate of
Any repurchases would be made in the open market and/or in privately negotiated transactions, and may be made from time to time or in one or more larger repurchases. The program will be conducted in compliance with the Securities and Exchange Commission's Rule 10b-18 and applicable legal requirements. The amount and timing of any repurchases made under the repurchase program will depend on a variety of factors, including available liquidity, cash flow and market conditions.
The program does not obligate the Company to acquire any particular amount of common stock and the program may be modified or suspended at any time at the Company's discretion.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes its core instruments, the Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the Aurora CS; the flow cytometer and imaging products under the Amnis® and Guava® brands; the Cytek Orion™ reagent cocktail preparation system, and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements other than statements of historical facts, including statements regarding our future activity, if any, under the share repurchase program, including the timing of any such repurchases, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. You should refer to the section entitled “Risk Factors” set forth in Cytek’s Quarterly Report on Form 10-Q filed on May 8, 2024 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s as of any date subsequent to the date of this press release.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
FAQ
What has Cytek Biosciences announced recently?
What is the duration of Cytek Biosciences' stock repurchase program?
Under what market symbol is Cytek Biosciences' common stock listed?
How will Cytek Biosciences conduct the stock repurchase?
What rule does Cytek Biosciences' repurchase program comply with?
Is Cytek Biosciences obligated to repurchase a certain amount of stock?
Can Cytek Biosciences modify or suspend the stock repurchase program?
